Highlights of weekly biotech stock moves

AB Science S.A. (Euronext:AB) fell €4 (21%) to €15 on Friday after EMA's CHMP issued a negative opinion recommending against approval of an MAA for Masican masitinib to treat gastrointestinal stromal tumors (GIST) that cannot be removed surgically or have progressed following treatment with Gleevec imatinib.

CHMP said it was "difficult to interpret" the results of the Phase II trial on which the MAA was based. CHMP was also concerned that safety data for the proposed dose of Masican were only available for a few patients, and also concerned about the quality control of the compound during the manufacturing process...